Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologymhn brensocatib Coverage & Prior Auth Policy Updat…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PMN.303

    Brensocatib (Brinsupri) — Coverage Criteria for Non‑Cystic Fibrosis Bronchiectasis

    Customize your policy alerts

    Sign up for mhn Policy CP.PMN.303 alerts

    Get alerted when Policy CP.PMN.303 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, authorization, and dosing for brensocatib (Brinsupri) for commercial, HIM, and Medicaid members and specifies requirements for prior authorization and continued therapy for patients age ≥12.

    Policy Summary
    Payermhn
    PolicyBrensocatib (Brinsupri) — Coverage Criteria for Non‑Cystic Fibrosis Bronchiectasis
    Policy CodePolicy CP.PMN.303
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation confirming CT‑confirmed non‑CF bronchiectasis, pulmonologist involvement, age ≥12, optimal supportive therapy, exacerbation history, negative cotinine test, and dose ≤25 mg/day.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12minimum covered age
    12 monthsapproval duration
    25 mg/daymaximum daily dose
    10 mg, 25 mgtablet strengths

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Brensocatib (Brinsupri)

    inv-01: Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval Criteria - Non-CF Bronchiectasis: 1) Diagnosis of non-cystic fibrosis bronchiectasis confirmed by chest CT scan; 2) Prescribed by or in consultation with a pulmonologist; 3) Age ≥ 12 years; 4) Provider attestation that member is currently receiving optimal supportive therapy (examples include but are not limited to airway clearance techniques, pulmonary rehabilitation, mucoactives, and antibiotics); 5) Documentation of one of the following despite ≥3 months of optimal supportive therapy: (a) Adults (≥18 years): ≥2 pulmonary exacerbations requiring systemic antibiotics in the last 12 months; (b) Pediatrics (12–17 years): ≥1 pulmonary exacerbation requiring systemic antibiotics in the last 12 months; 6) Member is not an active smoker as evidenced by a negative nicotine metabolite (cotinine) test within the last 30 days; 7) Member does not have a primary diagnosis of asthma or COPD (secondary/comorbid diagnoses allowed); 8) Dose does not exceed 25 mg per day.see node text

    Approval duration: 12 months

    inv-02: Continuation Therapy

    Covered when ALL of the following are met:

    Continued Therapy Criteria - Non-CF Bronchiectasis: 1) Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria; (b) currently receiving medication and enrolled in a state/product with continuity of care regulations; 2) Member is responding positively to therapy; 3) If request is for a dose increase, new dose does not exceed 25 mg per day.see node text

    Approval duration: 12 months

    This policy does not authorize coverage for non‑FDA approved indications that are not explicitly addressed. Requests for off‑label use must include sufficient documentation of efficacy and safety consistent with the applicable off‑label/no‑coverage policies referenced in this document (for example: CP.CPA.09, HIM.PA.154, CP.PMN.53). Absent adequate supporting evidence per those policies, coverage for non‑FDA indications will not be granted.

    For diagnoses or indications that do not meet the specified coverage criteria (for example, lacking chest CT confirmation of non‑cystic fibrosis bronchiectasis, not prescribed by or in consultation with a pulmonologist, patient age <12 years, absence of documentation showing the required pulmonary exacerbation history, not having documented at least 3 months of optimal supportive therapy, active smoking without a recent negative cotinine test, or a primary diagnosis of asthma/COPD), the request is considered not medically necessary and may be denied. Additionally, requests for non‑FDA indications without sufficient off‑label documentation are subject to denial per the referenced off‑label/no‑coverage policies.

    Product Coding and Dosing

    Product strengthsNDC | mixed
    10 mgTablet strength — 10 mg
    25 mgTablet strength — 25 mg
    Maximum daily dose
    Maximum daily dose25 mg per day (maximum of 1 x 25 mg tablet daily)
    Approved dosing regimens10 mg or 25 mg orally once daily
    Dose limit in initial criteriaDose does not exceed 25 mg per day (Initial Approval criterion 8)

    Prior Authorization & Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Provider must submit documentation (such as office chart notes, lab results, consultation notes, imaging reports) supporting that the member meets all approval criteria for initial and continued therapy.

    • A documented CT chest confirming non-CF bronchiectasis (initial requests)
    • Pulmonologist prescriber or consultation note (initial requests)
    • Recent nicotine metabolite test (within 30 days) showing negative cotinine for non-smokers (initial requests)
    • Documentation of prior pulmonary exacerbations and systemic antibiotic use per age-specific thresholds (see Initial Approval Criteria 5)
    • Evidence of enrollment in continuity-of-care program or prior approval history for continuation requests
    Documentation Required

    Supportive Therapy Requirement — Provider Attestation Required

    Provider must attest that the member is currently receiving optimal supportive therapy before initial approval will be granted. Examples of optimal supportive therapy include airway clearance techniques, pulmonary rehabilitation, mucoactive agents (e.g., nebulized hypertonic saline, mannitol, dornase alfa, acetylcysteine), and appropriate antibiotic therapy (e.g., oral azithromycin or erythromycin; inhaled tobramycin or aztreonam).

    • Attestation must appear in the submitted documentation (office notes, care plan, or consultation note).
    • Supportive therapy must have been used for at least 3 months prior to meeting exacerbation criteria (see Initial Approval Criteria 5).
    Documentation Required

    Required Documentation

    Acceptable documentation must be submitted with the prior authorization request to demonstrate that all criteria are met. Incomplete documentation may lead to denial.

    • Office chart notes or progress notes documenting diagnosis, supportive therapy, and clinical course
    • CT chest report confirming bronchiectasis (initial requests)
    • Pulmonologist consultation or prescriber note
    • Laboratory results, including recent cotinine/nicotine metabolite test (within 30 days) to confirm non-smoking status
    • Medication history and records of systemic antibiotic treatment for pulmonary exacerbations (dates and indication)
    • Pulmonary rehabilitation or airway clearance therapy documentation, as applicable
    Denial Risk

    Denial Triggers for Coverage

    Coverage may be denied if required conditions are not met or documentation is incomplete. Requests for non‑FDA approved indications will be denied unless sufficient supporting evidence is provided per applicable off‑label/medical necessity policies.

    • Missing provider attestation of current optimal supportive therapy (Initial Approval Criteria 4)
    • Lack of CT chest confirming bronchiectasis for initial requests
    • Insufficient documentation of required number of pulmonary exacerbations despite ≥3 months of supportive therapy (Initial Approval Criteria 5)
    • Positive nicotine metabolite (cotinine) test within 30 days indicating active smoking (Initial Approval Criteria 6)
    • Primary diagnosis of asthma or COPD listed as the primary reason for treatment (Initial Approval Criteria 7)
    • Dose request exceeding 25 mg (1 tablet) per day
    • Requests for indications not FDA‑approved without evidence meeting off‑label use policy requirements

    Clinical Background

    Brensocatib is a dipeptidyl peptidase 1 (DPP1) inhibitor approved for treatment of non‑cystic fibrosis bronchiectasis in patients aged ≥12 years. Dosing options include 10 mg or 25 mg once daily with a maximum daily dose of 25 mg. The pivotal trial definition for a pulmonary exacerbation required worsening of multiple major symptoms over a specified interval leading to systemic antibiotic treatment (see Appendix D in the clinical documentation).

    Definitions

    Pulmonary exacerbation
    DefinitionPulmonary exacerbation: worsening of ≥3 major symptoms over 48 hours resulting in a healthcare provider's decision to prescribe systemic antibiotics.
    Major symptom examplesIncreased cough; increased sputum volume or change in sputum consistency; increased sputum purulence; increased breathlessness; decreased exercise tolerance; fatigue and/or malaise; hemoptysis.
    Use in criteriaExacerbations counted are those requiring systemic antibiotics within the last 12 months (adults ≥18: ≥2; pediatrics 12–17: ≥1).
    DPP1
    TermDPP1 (dipeptidyl peptidase 1)
    RelevanceEnzymatic target of brensocatib (Brinsupri).
    ContextBrensocatib is a DPP1 inhibitor indicated for non-cystic fibrosis bronchiectasis in patients aged ≥12 years.
    Policy Summary
    Payermhn
    PolicyBrensocatib (Brinsupri) — Coverage Criteria for Non‑Cystic Fibrosis Bronchiectasis
    Policy CodePolicy CP.PMN.303
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation confirming CT‑confirmed non‑CF bronchiectasis, pulmonologist involvement, age ≥12, optimal supportive therapy, exacerbation history, negative cotinine test, and dose ≤25 mg/day.
    SourceLink
    On This Page
    Coverage Criteria for Brensocatib (Brinsupri)Product Coding and DosingPrior Authorization & Documentation RequirementsClinical BackgroundDefinitions